Nature Communications (Jul 2022)
Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement
- Jiaye Liu,
- Yang Wang,
- Chunyang Mu,
- Meng Li,
- Kewei Li,
- Shan Li,
- Wenshuang Wu,
- Lingyao Du,
- Xiaoyun Zhang,
- Chuan Li,
- Wei Peng,
- Junyi Shen,
- Yang Liu,
- Dujiang Yang,
- Kaixiang Zhang,
- Qingyang Ning,
- Xiaoying Fu,
- Yu Zeng,
- Yinyun Ni,
- Zongguang Zhou,
- Yi Liu,
- Yiguo Hu,
- Xiaofeng Zheng,
- Tianfu Wen,
- Zhihui Li,
- Yong Liu
Affiliations
- Jiaye Liu
- Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University
- Yang Wang
- Department of Medical Biochemistry and Biophysics, Karolinska Institute
- Chunyang Mu
- Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University
- Meng Li
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- Kewei Li
- Department of Pediatric Department, West China Hospital, Sichuan University
- Shan Li
- Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University
- Wenshuang Wu
- Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University
- Lingyao Du
- Center of Infectious Diseases, West China Hospital, Sichuan University
- Xiaoyun Zhang
- Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University
- Chuan Li
- Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University
- Wei Peng
- Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University
- Junyi Shen
- Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University
- Yang Liu
- Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University
- Dujiang Yang
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University
- Kaixiang Zhang
- Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University
- Qingyang Ning
- Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University
- Xiaoying Fu
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University
- Yu Zeng
- Department of Gastroenterology, West China Hospital, Sichuan University
- Yinyun Ni
- Respiratory Health Institute, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University
- Zongguang Zhou
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University
- Yi Liu
- Department of Rheumatology and Immunology, Rare Disease Center, West China Hospital, Sichuan University
- Yiguo Hu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center
- Xiaofeng Zheng
- Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University
- Tianfu Wen
- Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University
- Zhihui Li
- Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University
- Yong Liu
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University
- DOI
- https://doi.org/10.1038/s41467-022-31928-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Pharmacological inhibition of the prolyl isomerase PIN1, highly expressed in cancer cells and cancer associated fibroblasts (CAF), has been proposed for cancer therapy. Here the authors report the design of a DNA-barcoded micellular system functionalized with antibodies targeting CAFs and a T cell recruiting aptamer to deliver the PIN1 inhibitor AG17724, showing antitumor response in preclinical models of pancreatic cancer.
